$IBRX

ImmunityBio appointed Dr. Jim Yong Kim, former World Bank president, as Vice Chairman to expand international relationships and access to therapies. Kim will support partnerships with governments and health institutions. Jazz Pharmaceuticals agreed to acquire Actio Biosciences for $820 million upfront, potentially adding $500 million in milestones, to gain ABS-1230, a therapy for KCNT1-related epilepsy.

U.S. stock futures rose early Wednesday on Middle East deal hopes and AMD's strong earnings report. AMD stock surged 19% on $11.2B Q2 revenue outlook. NVO rose 8% after raising 2026 outlook. TSLA may face 25% EU tariff. Other stocks in focus include NVDA, SMCI, META, AAPL, IBRX, DGXX.

Sellas Life Sciences (SLS) and ImmunityBio (IBRX) are gaining attention as the biotech sector performs strongly. The SPDR S&P Biotech ETF (XBI) is up 17% in June, with SLS surging 53% and IBRX gaining 10%. Analysts highlight opportunities in immuno-oncology and cancer treatments, citing potential M&A activity and FDA support for innovation.

ImmunityBio (IBRX) shares fell 3% after reporting Phase 2 trial results showing ANKTIVA plus BCG significantly improved bladder cancer responses. The company plans a 2026 FDA application, with Q4 revenue up 431% to $38.3M. Retail sentiment remains bullish.

Virginia Retirement System disclosed stakes in Sellas Life Sciences (SLS) and ImmunityBio (IBRX), with holdings valued at $909,000. SLS shares rose 41% in August, while IBRX gained 14%. SLS is awaiting final analysis of its Phase 3 trial for AML, with results potentially supporting an FDA application. IBRX is planning trials combining radiation and immune activation, and awaits an FDA decision on Anktiva's label expansion.

ImmunityBio (IBRX) appointed Dr. Jim Yong Kim as Vice Chairman to enhance global relationships and access for its immunotherapies. The company projects $1.6B revenue and $673.2M earnings by 2029, requiring significant growth. Kim's expertise may support international expansion, though risks remain.

ImmunityBio (IBRX) shares rose 7% to $10.44 on Monday, extending a three-day rally. Founder Patrick Soon-Shiong called a recent speech a prelude to Tuesday's 2025 earnings report, criticizing traditional cancer treatments and highlighting Anktiva's IL-15 mechanism. The company expects $113M in 2025 revenue, up 700% YoY, with losses narrowing. Fiscal AI estimates 2025 revenue at $113.29M and loss per share at $0.38.

Moderna (MRNA) and Merck (MRK) reported positive Phase 3 trial results for their cancer vaccine, Intismeran Autogene, boosting shares. Analysts raised sales forecasts and approval probabilities. Sellas Life Sciences (SLS) and ImmunityBio (IBRX) are also in focus due to their oncology work. MRNA surged 177%, MRK gained 13%, and other related stocks saw significant moves.

ImmunityBio (IBRX) shares rose 1% in overnight trading ahead of Tuesday's earnings report. The company expects to narrow losses in 2025, with revenue projected to rise to $113.29 million. Anktiva, its lead immunotherapy, saw strong commercial traction, with 2025 net product revenue up 700% to $113 million. Founder Patrick Soon-Shiong highlighted Anktiva's potential in media appearances, citing positive clinical trial results and FDA remarks.

U.S. stock futures rose early Wednesday ahead of Nvidia's earnings report and Fed minutes release. Nvidia (NVDA) announced a Google Cloud partnership. Tesla (TSLA) saw retail speculation over a potential SpaceX merger. ImmunityBio (IBRX) and Sellas Lifesciences (SLS) rose on positive news. Nio (NIO) and Boeing (BA) faced mixed sentiment. Investors also await earnings from Target (TGT) and others.